Daiki Tsuji

10PUBLICATIONS
21CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Epidemiological modellingPharmacogenomics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Jun 01, 2026
Pharmacogenomic profiling of the efficacy of gemcitabine monotherapy in metastatic pancreatic cancer: Subgroup analysis of the GENESECT study.

|Mar 06, 2026
NFE2L2 rs35652124C>T polymorphism predicts Grade 4 neutropenia in esophageal cancer patients treated with docetaxel, cisplatin, and fluorouracil chemotherapy: results from exploratory and validation cohorts.

Hisanaga Nomura, Takaya Suzuki, Takashi Kojima

|Aug 27, 2025
Development of a predictive model for neutropenia risk in Japanese breast cancer patients treated with doxorubicin and cyclophosphamide.

Takehiro Miyagi, Daiki Tsuji, Eiji Nakatani

|Nov 16, 2024
A multicenter, phase II trial of triplet antiemetic therapy with palonosetron, aprepitant, and olanzapine for highly emetogenic chemotherapy in breast cancer (PATROL-II).

Kenichi Suzuki, Takashi Yokokawa, Takashi Kawaguchi

|Apr 29, 2024
Pharmacogenomic study of gemcitabine efficacy in patients with metastatic pancreatic cancer: A multicenter, prospective, observational cohort study (GENESECT study).

Masahiro Hatori, Daiki Tsuji, Kenichi Suzuki

|Jan 03, 2024
Changes in estimated glomerular filtration rate in patients administered proton pump inhibitors: a single-center cohort study.

Takuma Murofushi, Tatsuya Yagi, Daiki Tsuji

Pageof 2

Frequent Collaborators

4 joint publications

Takashi Yokokawa

4 joint publications

Kunihiko Itoh

3 joint publications

Masahiro Hatori

2 joint publications

Yasukata Ohashi